Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
Psychemedics (NASDAQ: PMD), a leading entity in hair testing for drugs, has launched its inaugural Insights Report. This comprehensive report analyzes drug trends in the workplace, derived from hundreds of thousands of hair samples collected in 2023. The report reveals an overall positive drug test rate of 9.5%, with a 23% increase in positive rates over the last five years. Marijuana, cocaine, and opiates are the most detected substances, while fentanyl shows a troubling rise. The report underscores the effectiveness of hair testing for employment drug screening and aims to help employers and policymakers address workplace drug use. More details can be accessed at the provided link.
- Launch of the inaugural Insights Report demonstrates leadership in drug testing.
- Comprehensive analysis from hundreds of thousands of hair samples enhances report credibility.
- Overall positive drug test rate of 9.5% provides critical industry data.
- Identified a 23% increase in positive drug test rates over the past five years, indicating changing trends.
- Marijuana, cocaine, and opiates as commonly detected substances offer actionable insights for employers.
- Increase in fentanyl presence signals an escalating drug use challenge in the workplace.
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.
As pioneers in the field of hair testing, Psychemedics collected hundreds of thousands of hair samples from individuals across diverse industries and regions. Leveraging advanced analytical techniques, the Psychemedics team meticulously analyzed these samples to detect a wide range of drugs and metabolites, forming the foundation of the insights.
The 2024 Insights Report serves as a testament to the efficacy and advantages of hair testing as the premier method for employment drug screening. It highlights key findings and trends, including:
- Positive Rate for Drugs Tested: An overall positive rate of
9.5% underscores the significant presence of drug use in the workplace. - Trend Over 5 Years: Over the past five years, our analysis revealed a notable
23% increase in positive drug test rates across various industries. - Marijuana, Cocaine, and Opiates: These substances maintained a notable presence, with marijuana being the most commonly detected.
- Rising Trend in Fentanyl: An alarming increase in fentanyl presence over the last couple of years emphasizes the urgency for targeted interventions and testing.
“In our inaugural report, Psychemedics is proud to unveil a comprehensive analysis of workplace drug use trends,” stated Brian Hullinger, President and Chief Executive Officer at Psychemedics. “As an industry leader in hair testing, Psychemedics remains committed to advancing the field of drug testing and providing innovative solutions to create safer and more productive workplaces.”
The 2024 Psychemedics Insights Report serves as a vital resource for employers, policymakers, and stakeholders seeking to understand and address the complex challenges posed by drug use in the workforce. To access the full report and learn more about Psychemedics’ pioneering hair testing solutions, visit https://www.psychemedics.com/wp-content/uploads/2024/06/PMD-2024-Workforce-Insights-Report.pdf.
For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit https://www.psychemedics.com.
About Psychemedics
Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.
Investor Relations:
Phone: 978-206-8220
Email: InvestorRelations@psychemedics.com
FAQ
What did Psychemedics' 2024 Insights Report reveal about workplace drug use?
Which drugs were most commonly detected in Psychemedics' 2024 Insights Report?
What concerning trend did Psychemedics' report highlight?
How can employers benefit from Psychemedics' 2024 Insights Report?
Where can I access Psychemedics' full 2024 Insights Report?
